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Abstract Hemogenic endothelium is a specialized subset
of developing vascular endothelium that acquires
hematopoietic potential and can give rise to multilineage
hematopoietic stem and progenitor cells during a narrow
developmental window in tissues such as the extraembry-
onic yolk sac and embryonic aorta-gonad-mesonephros.
Herein, we review current knowledge about the historical
and developmental origins of hemogenic endothelium, the
molecular events that govern hemogenic specification of
vascular endothelial cells, the generation of multilineage
hematopoietic stem and progenitor cells from hemogenic
endothelium, and the potential for translational applica-
tions of knowledge gained from further study of these
processes.
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Introduction
Normal embryogenesis is predicated upon the development
of a functioning cardiovascular system early in gestation—
disruptions in this lead to vascular, cardiac, hematologic
disease, and in extreme cases embryonic lethality. As the
primitive vasculature expands throughout early develop-
ment, it remodels and specializes to fulfill the critical
metabolic demands of the tissues it supplies [1]. As part of
this remodeling, endothelial cells lining the cardiovascular
system subspecialize to arterial, venous, lymphatic, and
hemogenic fates via a complex network of intersecting
molecular pathways. The mechanisms underlying normal
vascular development remain as yet incompletely defined,
and a greater understanding of these processes will enhance
our understanding of certain pathologic states related to the
vascular system and how they might be treated.
Hemogenic endothelium is a small, specialized subset of
vascular endothelium that acquires hematopoietic potential
and can give rise to multilineage hematopoietic stem and
progenitor cells (HSPC) within a narrow developmental
window within distinct tissues [1]. Work in the last decade
has begun to clarify the complex signals that lead to
acquisition of this blood-forming potential. Our under-
standing of the events that lead to hemogenic specification
of endothelial cells from vascular endothelium, as well as
the events that lead to generation of HSPC from hemogenic
endothelium is still in its infancy. This review will outline
current knowledge about the historical and developmental
origins of hemogenic endothelium, the molecular events
that govern hemogenic specification of vascular endothelial
cells, the generation of multilineage HSPC from
hemogenic endothelium, and the potential for clini-
cal/translational applications of knowledge gained from
further study of these processes.
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Developmental and historical origins of hemogenic
endothelium
Primitive hematopoiesis
Hematopoiesis occurs in two waves during embryonic
development—the primitive (precirculation) wave and
definitive wave. The first blood and endothelial cells are
derived from the extraembryonic mesoderm beginning
around embryonic day (E) 7.0 [2]; whether they are derived
from a common bipotent progenitor (hemangioblast), or are
independently fated, remains a subject of debate, as dis-
cussed later in this review. Primitive hematopoiesis is
marked by the brief emergence of mostly nucleated ery-
throid progenitors, as well as macrophage progenitors [3],
that are generated in parallel with endothelial cells. These
primitive erythroid cells are functionally and morphologi-
cally distinct from later erythroid progenitors in that they are
large, nucleated, express embryonic globins, and are
exclusively detected in the extra-embyonic yolk sac during a
narrow (*48 h) window before they disappear [3]. Other
precirculation extra-embryonic sources of pro-definitive
erythroid and myeloid progenitor cells later emerge between
E7.5 and E8.0 and include the allantois [4, 5] and para-aortic
splanchnopleura (pSP) [6, 7]. These early cells are of great
importance to the developing embryo as they sustain
embryonic survival until the definitive hematopoietic system
is established, and they form structures referred to as ‘‘blood
islands’’ around E7.5 [8], in which the cells in the interior
give rise to nucleated erythroid and myeloid cells and those
on the periphery become lumenized endothelial cells [1].
Blood islands then coalesce to form vascular channels and a
plexus network throughout the yolk sac, which conducts
oscillatory plasma flow driven by the developing heart tube
[9]. By E8.25, a second wave of erythromyeloid progenitor
(EMP) cells are generated which also give rise to tissue
macrophages that persist into adulthood [10–12]. Following
the onset of plasma flow, the immature progenitor cells join
the plasma circulation [3, 13].
Definitive hematopoiesis
Definitive hematopoiesis is the second phase of blood
production beginning with production of erythroid and
myeloid progenitors that is then followed by generation of
long-term repopulating hematopoietic stem cells (HSC)
capable of colonizing hematopoietic organs and giving rise
to all differentiated blood lineages [14, 15]. Definitive
hematopoiesis coincides with the onset of pulsatile blood
flow due to coordinated cardiac contraction beginning
around E8.25, as the first wave of extra-embryonic
primitive erythroid progenitors previously described
decrease in number and the previously described second
yolk sac wave of erythroid and myeloid cells are generated
and enter the plasma circulation [3, 14, 16]. Generation of
hematopoietic progenitors then begins in the placenta
between E9.0 and 9.5 [17–20]. In the murine embryo
proper, definitive hematopoiesis occurs later, within the
aorta-gonad-mesonephros (AGM) region peaking at E10.5
[21–23] and is marked by the generation of both progenitor
cells, as well as HSC. These AGM and yolk-sac-derived
hematopoietic stem and progenitor cells are thought to
migrate to, and colonize other sites of definitive hemato-
poiesis, most notably the fetal liver by E11.0–E12.0 [24–
26] and the bone marrow at E16.5 [27], and contribute to
the adult HSC pool. While it is clear that progenitor cells
emerge from the yolk sac and placental tissues during
definitive hematopoiesis, it remains debated whether or not
the placenta and yolk sac actually generate HSC de-novo—
although it has been shown that the number of HSC col-
onizing the fetal liver is greater than what can be accounted
for by the AGM alone [26]. This suggests that additional
sources of HSC, such as the placenta and yolk sac, may
exist and contribute to the HSC pool used by the liver for
self-expansion [14, 18, 26, 28]. It also remains unclear
whether there exists de-novo generation of HSC within
fetal liver, fetal bone marrow or postnatal tissues, or if HSC
are merely replenished via self-renewal of yolk sac- and
AGM-derived cells [29].
While it has been demonstrated that the yolk sac and
AGM are sites of definitive hematopoiesis, the cellular
origins of the HSPC within these tissues is still under
investigation, and may be different in distinct species.
Nonetheless, it is generally thought that murine definitive
HSPC are derived from a small subset of vascular
endothelium that acquires hemogenic potential, so-called
hemogenic endothelium. Interestingly, hematopoietic cells
produced by hemogenic endothelial cells have different
functional characteristics depending on their site of origin
[29]. That is, yolk sac hemogenic endothelial cells give rise
to multilineage hematopoietic progenitors that cannot
repopulate neonatal or adult bone marrow long-term
in vivo [7], and are therefore referred to as multilineage
progenitors. In contrast, AGM-derived hematopoietic cells
are capable of rescuing irradiated neonatal and adult
recipients [30]; thus, these cells are considered definitive
HSC. This raises the possibility that not all hemogenic
endothelial cells are created equally, or that their anatomic
niche influences their function and progeny, in a manner
dependent on the developmental timing of their emergence
and/or the cellular and extracellular composition of their
microenvironment [29].
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Concept evolution of hemogenic endothelium
To best understand the significance of hemogenic
endothelial cells in embryonic hematopoiesis, it is useful to
consider the evolution of the concept of their existence and
function over the course of the last century. Insights gained
during their discovery, identification and characterization
have helped intertwine the fields of hematopoietic stem cell
biology and vascular biology. The concept of hemogenic
endothelium dates back in the scientific literature to the late
19th century. Beginning in 1899, several anatomists
observed an association of blood forming cells with
developing vascular structures across a wide variety of
mammalian species including the bat (1899), chick (1907),
rabbit (1909), human (1912), pig (1916), and mongoose
(1917) [15]. In 1917, anatomist Florence Sabin directly
observed in chick embryo studies that ‘‘red blood-corpus-
cles can be seen to grow from the endothelial lining of
blood-vessels’’ [31]. These blood cells were then noted to
bud off from vascular endothelial cells into plasma flowing
through primitive vascular plexus of the developing chick.
In the 1930s, Murray re-branded Sabin’s ‘‘angioblast’’
as a ‘‘hemangioblast’’ or a subset of mesenchymally-
derived primitive endothelium that transiently acquires
blood-forming potential [32]. Over the next several dec-
ades, however, this concept of the hemangioblast and the
questions surrounding an association between vascular
endothelium and blood formation went largely unad-
dressed. In the 1960s, Moore and Owen suggested that all
embryonic hematopoiesis occurred in the extra-embryonic
yolk sac, and that intra-embryonic blood in later stages of
development was a result of migration of yolk sac derived
hematopoietic progenitors [15]. This concept of exclu-
sively extra-embryonic hematopoiesis was refuted by
Dieterlen-Lie`vre and coworkers in 1975 when they
demonstrated intraembryonic aortic hemogenesis in quail-
chick embryo grafting experiments and renewed interest in
the origin of hematopoietic stem and progenitor cells in the
developing embryo [15, 33].
The hemangioblast
Over the next two decades, several groups corroborated the
work of Dieterlen-Lie`vre and coworkers by demonstrating
the presence of hematopoietic stem and progenitor cells in
the ventral aspect of the developing dorsal aorta prior to
hepatic colonization, and demonstrated that these cell
clusters are necessary for the establishment of definitive
hematopoiesis [6, 15, 23, 24, 34, 35]. This confirmed
association of hematopoietic cells with vascular endothe-
lium brought into question the developmental relationship
between hematopoietic cells and vascular endothelium—
were they two independent lineages derived from discrete
progenitor cell types or did they have a common meso-
dermally-derived bipotent cell progenitor, the so-called
hemangioblast, that transiently gives rise to vascular
endothelial and blood cells? [29]. Indeed, endothelial and
hematopoietic lineages have been shown to share many
common surface markers and transcription factors that are
implicated throughout their differentiation. These include
mesodermal markers Brachyury (Bry), bone morphogenic
protein 4 (BMP4), and vascular endothelial growth factor 2
(VEGFR2 or Flk-1) [36]; shared markers CD34, VE-cad-
herin, and CD31; and common transcription factors
RUNX1 and GATA binding protein 2 (GATA2) [37],
lending credibility to the hemangioblast concept. However,
to date, there is a lack of convincing evidence to suggest
that such an exclusively bipotent mesodermal progenitor
exists [29].
The bipotent hemangioblast has been described as co-
expressing mesodermal marker Bry and Flk-1, but
Bry?Flk-1? cells have, in fact, been demonstrated to give
rise to cardiac, skeletal, and vascular smooth muscle, as
well as endothelial cells and blood cells [38, 39]. Padro´n-
Barthe and coworkers demonstrated by in vivo clonal
analysis of murine embryos that the earliest blood and
endothelial lineages do not arise from a primitive streak-
derived bipotential precursor, but that these lineages are
derived from independent epiblast populations [40]. These
results are consistent with previous mesodermal grafting
studies that also suggest endothelial and blood cell lineages
are independently fated during primitive hematopoiesis
[41]. It remains possible that there may exist a bipotent
mesodermal progenitor giving rise to exclusively
endothelial and blood cells, but this has not been defini-
tively demonstrated to date [29]. A middle ground to the
hemangioblast debate was proposed by Lancrin and
coworkers, wherein the mesodermally-derived heman-
gioblast gives rise to an endothelial intermediate
(hemogenic endothelium) that then gives rise to HSPC
[42].
Hemogenic endothelium
Despite the uncertainty of the existence of hemangioblasts
during primitive hematopoiesis, several landmark studies
over the last two decades have provided strong evidence
that during definitive hematopoiesis in vertebrates, multi-
potent HSPC arise directly from transiently specialized
vascular endothelium (hemogenic endothelium) within the
developing AGM between E10.0 and E11.5, prior to
appearance in other intra-embryonic hematopoietic organs
[6, 23, 24, 34, 35].
The aforementioned early observations of blood cells
budding from vascular endothelium have been corrobo-
rated by dye-labeled fate tracing approaches that
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demonstrate across multiple animal models that dye-tagged
vascular endothelium in the dorsal aorta gives rise to dye-
tagged circulating blood cells [43, 44]. Subsequent in vivo
fate tracing studies in murine embryos has further
demonstrated emergence of HSC from endothelium from
VE-cad? cells in the dorsal aorta that go on to colonize
intra-embryonic hematopoietic sites including the bone
marrow, spleen, and thymus [45].
Hematopoietic stem and/or progenitor cell emergence
has also been shown to occur within the vascular plexi
within the extra-embryonic yolk sac [13, 46, 47], placenta
[18], as well as the vitelline artery, umbilical arteries [21,
48, 49], endocardium [50], and head arteries [51]. Multiple
real-time imaging studies demonstrating hematopoietic cell
emergence from vascular endothelium have been performed
in mice and zebrafish [52–54]. Single cell lineage tracing
studies have demonstrated multipotent HSPC with cell
surface markers CD31 (endothelial cell marker), CD41
(blood cell marker), c-Kit (stem cell growth factor recep-
tor), and SCA-1 (stem cell antigen, also known as Ly6A)
arising directly from the ventral wall of the murine dorsal
aortae that can be traced to the fetal liver [53], and ulti-
mately to the adult hematopoietic system in mice [45] and
in zebrafish [52, 54].
Several studies have addressed the question of whether
vascular-derived hematopoiesis truly originates from
endothelial cells and is not mesenchymal in origin. In 2002,
de Bruijn and colleagues demonstrated using a Ly6A(SCA-
1)-GFP transgenic mouse model that all hematopoietic
stem cells within the developing aorta are Ly6A-GFP? and
that these cells localize to the endothelial layer of the
dorsal aorta, but not to the underlying mesenchyme [55].
To further support the assertion that HSPC are generated
from an endothelial intermediate and not the underlying
mesenchyme, it has been demonstrated that key
hematopoietic regulators such as the transcription factor
RUNX1 are expressed at high levels by endothelial cells in
hemogenic vascular sites in vertebrates [56]. North and
colleagues further demonstrated that while RUNX1-ex-
pressing HSC are found in both endothelial and
mesenchymal cell fractions in the mouse embryo, the
presence of two functional Runx1 alleles segregates HSC to
the endothelial fraction only [57]. More recently, it has
been shown that Runx1 deletion in VE-cadherin expressing
endothelial cells results in loss of intra-aortic hematopoi-
etic cluster formation, again corroborating the link between
cells of endothelial origin giving rise to hematopoietic
clusters via the action of known hematopoietic mediators
such as RUNX1 [58]. Additionally, murine AGM-associ-
ated hemogenic endothelial cells give rise to either
hematopoietic or endothelial lineages but never both [59]
and human pluripotent stem cell-derived arterial endothe-
lial cells and hemogenic endothelial cells can be
distinguished on the basis of CD184 and CD73 expression
[60].
These studies collectively demonstrate, on a functional
as well as morphological level, a strong body of evidence
for the existence of hemogenic endothelial cells of exclu-
sively vascular origin that give rise to multilineage HSPC
during definitive hematopoiesis. However, much less is
known about the mechanisms underlying hemogenic
specification and their subsequent generation of HSPC.
Characterization of hemogenic endothelium
In order to characterize the molecular events underlying
hemogenic endothelial cell specification and their subse-
quent generation of HSPC, it is necessary to delineate the
phenotype of hemogenic vs. non-blood forming endothe-
lium, so that they can be effectively isolated and studied.
Isolation of these cells proves to be a difficult undertaking
as hemogenic endothelium represents a small (*1–3 % of
murine yolk sac and AGM endothelial cells) and transient
population within hematopoietic tissues [13, 61].
To date, no definitive single marker to distinguish
hemogenic from nonhemogenic endothelial cells has been
identified. Building upon the body of evidence supporting
the very existence of hemogenic endothelium, several
groups have used flow cytometry techniques to elucidate
the phenotypic identity of hemogenic endothelial cells
within the yolk sac and AGM to aid in their isolation and
further study. In 1997, Kabrun and colleagues described
generation of HSPC from Flk1? endothelium [62]. Shortly
thereafter, Nishikawa and colleagues isolated VE-
cad?CD45-Ter119- cells from the yolk sac and caudal
half of embryo proper of E9.5 mouse embryos and
demonstrated that this cell fraction was capable of giving
rise to lymphohematopoietic cells in culture. This study
confirmed that the VE-cad? cell fraction co-expressed
vascular markers CD34, CD31, and Flk-1, confirming that
the isolated cells were indeed endothelial in origin and
confirming both the existence and functional capability of
hemogenic endothelium to give rise to blood progenitors
[63]. The need for VE-cadherin expression was further
corroborated by a subsequent study by Fraser and col-
leagues that demonstrated long term lyphohematopoietic
reconstitution potential of VE-cad?/CD45- cells injected
into irradiated neonatal mouse recipients [30]. Hemogenic
endothelial cells can also be distinguished from non-
hemogenic endothelial cells based on differential activity
of a regulatory element of a KDR promoter enhancer such
1550 E. Gritz, K. K. Hirschi
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that only nonhemogenic endothelial cells activate the
enhancer [64]. Other studies have since shown that cells
co-expressing CD31, CD34, and Flk-1 from both murine
and human yolk sac and AGM have demonstrated lympho-
and lymphomyelopoietic potential under culture conditions
[1, 63, 65]. In addition, cells co-expressing Flk-1 and VE-
cadherin exhibit enhanced colony forming ability when
compared to Flk-1?VE-cad- cells [30]; however, VE-
cadherin expression was not found to be necessary for the
blood-forming ability of yolk sac hemogenic endothelial
cells in mice [13] or for transition of hemogenic endothelial
cells to HSC in zebrafish and mice [66]. It has been shown
as well that hemogenic endothelial cells may actually be
divided into functionally distinct populations that either
generate erythroid and myeloid progenitor cells or exclu-
sively generate HSC [67].
Alpha4-integrin (a4-integrin) has been identified as a
marker that distinguishes hemogenic VE-cad? cells from
nonhemogenic VE-cad? cells [68]. Live cell time-lapsed
imaging of embryonic stem cell-derived Flk1?VE-cad-
mesodermal cells co-cultured with OP9 stromal cells
demonstrated transformation of VE-cad?DI-acyl
LDL? cells with Claudin5 mediated-tight junctions into
sheets of cells with endothelial morphology that gave rise to
non-adherent, free-floating round CD45?CD41? he-
matopoietic progenitor cells [69]. Loss of endothelial
markers and acquisition of hematopoietic markers was
shown to proceed in a patterned fashion in this model. More
recently, a critical role for Stem cell leukemia (SCL) factor
in maintenance of hemogenic competence and prevention of
cardiomyocyte programming of primitive vascular
endothelial cells has been identified [70]. In other recent
studies, single hemogenic and non-hemogenic endothelial
cells could be isolated from Runx1 enhancer-reporter mice,
which was beneficial for transcriptional profiling of these
cell types [59, 69].
Further phenotypic characterization of hemogenic
endothelial cells by our group has revealed that blood-
forming activity of both yolk sac and AGM tissues is con-
tained within the Hoechst dye effluxing, or ‘‘side
population’’ (SP) fraction of cells [13, 61, 71], which is not
surprising given that the SP phenotype is also a character-
istic of HSC within adult bone marrow [72]. SP cells within
the yolk sac and AGM were further fractionated based on
endothelial and hematopoietic cell surface markers, and the
phenotype of hemogenic endothelium therein has been
defined, on a clonal level, as Flk-1?c-Kit?CD45- SP cells
[13, 61, 71]. In addition, the Flk-1?c-Kit?CD45- SP
hemogenic endothelial cells were demonstrated to give rise
to multilineage HSPC that are Flk1-c-Kit?CD45? SP
cells [13], that can be distinguished from mature blood cell
types with a Flk1-CD31±CD45? non-SP phenotype.
Specification of hemogenic endothelium
Despite these knowledge gains about the characteristics of
hemogenic endothelium over the last decade, little is
known about the hierarchy of molecular events that govern
their specification from non-blood forming endothelium, as
well as the events that lead to their generation of HSPC.
However, this body of knowledge is growing and recent
advances in our understanding are discussed below (and are
summarized in Fig. 1).
Retinoic acid signaling
Retinoic acid (RA) is known to regulate murine endothelial
cell development and specification [73, 74]. Biologically
active retinoic acid, known as all-trans retinoic acid
(ATRA), is derived from retinol (Vitamin A) via oxidation
by retinaldehyde dehydrogenases (RALDH1-3). ATRA is
then released, taken up by target cells, and bound to
members of the retinoic acid receptor (RAR) family (a, b,
or c). Heterodimerization of RAR family members with
rexinoid receptors (RXR) a, b, and c form active tran-
scription factor complexes that bind to retinoic acid
response elements within target genes to initiate tran-
scription (reviewed in Marcelo[1] and Chanda [75]).
During vasculogenesis in the murine yolk sac, active RA
is generated by RALDH2 expressed in the visceral endo-
derm, which then signals within endothelial cells in the
adjacent mesoderm that selectively express RAR a-1 and
a-2 [73]. Raldh2-/- mutant embryos exhibit abnormal
vascular development, due to hyperproliferative endothe-
lial cells [74], as well as anemia, and die around E10.0
[76]. Other work has demonstrated that mice deficient for
RA receptors have impaired fetal hepatic erythropoiesis
[77] as well as impaired generation of marrow-derived
HSC [78]. Because of its essential role in endothelial cell
development, as well as embryonic and postnatal hemato-
poiesis, RA signaling is of great interest in the study of
specification of endothelial cells to a hemogenic state.
Although Raldh1 and Raldh3 null embryos have not
been shown to exhibit hematologic defects [79], embryos
lacking Raldh2 were shown to exhibit defects in definitive,
but not primitive hematopoiesis [13, 75]. In addition, we
found that the underlying hematopoietic defect in Rald-
h2-/- mutants is lack of hemogenic endothelial cell
development, which could be rescued via provision of
bioactive RA to Raldh2-/- embryos in utero or in culture
[13, 61]. RA signaling is critical for the development of
hemogenic endothelial cells within the yolk sac, as well as
AGM. In both tissues, *90 % of endothelial cells with
active RA signaling exhibit a hemogenic phenotype;
in addition, *90 % of hemogenic endothelial cells are
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undergoing active RA signaling during definitive hemato-
poiesis in these tissues [61, 75]. These findings place RA at
or very near the top of the signaling hierarchy governing
hemogenic endothelial cell specification and function
during definitive hematopoiesis [13].
Notch
The Notch signaling pathway is evolutionarily conserved
and involved in many aspects of embryonic development,
with notable roles in vascular and cardiac development.
Mammals express four members of the Notch family of
receptors (Notch1-4) and five ligands: Delta-like 1, 3, 4
(DLL) and Jagged 1 and 2 (Jag). The interactions between
the receptors and ligands allow signal transduction between
neighboring cells via a multistep proteolytic cleavage of
the Notch receptor and subsequent release of the Notch
intracellular domain (NICD) (reviewed in High 2008 [80]).
A c-secretase complex powers the final step of release of
NICD into the cytoplasm, wherein NICD can then enter the
nucleus to form active transcriptional complexes with
RBPJ, and co-activator Mastermind-like (MAML) [80].
The pathway itself appears straightforward, in theory, but
is regulated by several positive and negative feedback
loops whose actions are determined by both cellular con-
text, developmental timing, and local environment [80].
Notch signaling is well known to be involved in cell fate
decisions and cell differentiation, particularly in endothe-
lial and blood cells, and a growing body of evidence also
points toward its involvement in hemogenic specification.
Embryos lacking Notch1 or Notch1 and Notch4 receptors,
the only receptors expressed by endothelial cells [81, 82],
exhibit abnormal vascular development similar to Raldh
2-/- mutants [74, 83, 84], and the expression of Notch1,
and its downstream effectors HES1 and HEY1, which are
known to regulate hematopoiesis [85] are upregulated in
endothelial cells by RA [61]. In addition, chemical inhi-
bition of Notch signaling in E8.0 wild-type mouse embryos
via use of c-secretase inhibitor DAPT suppresses yolk sac
hemogenic endothelial cell specification [61]. Notch1,
specifically, is expressed in the ventral wall of the dorsal
aorta where hemogenic endothelium forms (reviewed in
Jang 2015 [86]), and the AGM of Notch1-/- mutants
exhibit decreased hematopoietic activity (reviewed in Zape
2011 [37, 87]). Conversely, Notch1 induction in murine
embryonic stem cells leads to an expansion of VE-
cad? hemogenic endothelial cells with enhanced
hematopoietic potential [86]. These data collectively sug-
gest that Notch1 receptor signaling may regulate
hemogenic endothelial cell specification and function, and
also place Notch downstream of RA in the signaling
hierarchy governing hemogenic specification.
c-Kit
c-Kit (CD117) is a growth factor receptor with tyrosine
kinase activity known to bind stem cell factor (SCF), which
leads to dimerization of receptors and subsequent activa-
tion or regulation of kinase activity that modulates
intracellular signal transduction pathways involved in cel-
lular proliferation, maintenance and migration [1]. Such
pathways include Src kinase, PI3K, JAK-STAT, MAPK,
and PLCc, as well as regulatory PTPases, phosphatidyli-
nositol phosphatases, and protein kinase C [88]. SCF is
known to support multilineage hematopoietic development
[88] and c-Kit mutations are associated with embryonic
Fig. 1 Summary of regulation of primitive hematopoietic specifica-
tion and generation of hematopoietic stem cells during embryonic
development. a Schematic representation of endothelial layer of
developing vascular wall (pink), listed are intra- and extraembryonic
sources of vascular endothelial cells with hemogenic potential (blue
box). b Schematic representation of progression of events and
molecular signals governing hemogenic specification (orange boxes)
and c endothelial to hematopoietic transition (green boxes), ending
with generation of intra-vascular hematopoietic clusters and multi-
lineage hematopoietic stem and progenitor cells (HSPC)
1552 E. Gritz, K. K. Hirschi
123
lethality at midgestation, anemia and disrupted HSC
development [88, 89]. As previously noted, the expression
of c-Kit is a distinguishing feature of hemogenic
endothelial cells, relative to non-blood forming endothelial
cells. In addition, Notch1 expression in endothelial cells is
upregulated downstream of c-Kit; thus, this pathway
appears to play a critical, yet still undefined role, in the
signaling hierarchy that governs hemogenic endothelial
cell specification [61].
Cell cycle control/p27
Retinoic acid-deficient and Notch-inhibited embryos simi-
larly exhibit endothelial cell hyper-proliferation, and
impaired hemogenic endothelial cell development. We
found that downregulation of cell cycle inhibitor p27,
which induces G1 arrest [73, 74], to be the underlying
defect in RA-deficient embryos. Furthermore, p27 is
upregulated downstream of Notch and c-Kit, and lentivirus
mediated re-expression of p27 in both RA- and Notch-
inhibited murine yolk sac endothelial cells rescues
endothelial cell cycle control, hemogenic specification, and
the generation of HSPC [61]. Given that cell cycle state
and duration of G1 phase have been shown to be deter-
minants of stem cell fate [90–92], it is possible that
endothelial cells must be arrested in G1 phase in order to
undergo hemogenic specification. In fact, several tran-
scriptional regulators of definitive hematopoiesis are
differentially expressed in G1 phase (reviewed extensively
in [93]). It is also possible that p27 functions as a tran-
scriptional regulator to directly alter endothelial cell
phenotype, given that it can repress multipotency genes in
stem cell populations [94]. Thus, the RA/c-Kit/Notch sig-
naling axis which mediates p27 expression may regulate
hemogenic specification in at least two ways: (1) via
repression of genes that maintain a multipotent state in
primordial endothelial cells or induction of hemogenic
genes; and/or (2) elongation of G1 phase of cell cycle to
enable expression and accumulation of transcriptional
regulators that alter endothelial cell phenotype [61].
Generation of hematopoietic stem/progenitor cells
from hemogenic endothelium
The process by which HSC are generated from hemogenic
endothelium is referred to as the endothelial-to-he-
matopoietic transition (EHT; depicted in Fig. 1). In order
to be able to derive HSC from pluripotent stem cells for
clinical and research applications, an understanding of the
events that lead to HSC formation from endothelial cells
in vivo is required. The events leading to HSC generation
from an endothelial intermediate at multiple anatomic sites,
including the yolk sac, placenta, and AGM, involves an
incompletely characterized complex interplay between
microenvironment, developmental timing, and transcrip-
tional regulation of fate.
The AGM as a source of HSC
Prior to the onset of circulation, it has been shown that
lymphocyte and myeloid progenitors emerge as early as
E7.5 within the para-aortic splanchnopleura (pSp) [6] and
that explants of pSp demonstrate long-term hematopoietic
reconstitution ability whereas yolk sac explants demon-
strate only short term myeloid reconstitution ability [7].
Similar results were found in Xenopus studies that
demonstrated HSC emergence from dorsal aortic tissue that
derived from a blastomere independent of the yolk sac
[95]. The implication of this is that long-term repopulating
stem cells, or HSC, are intra-embryonic in origin. Work by
several groups led to the discovery of intra-aortic
hematopoietic clusters (IAHC) arising from the endothelial
lining of ventral wall of the dorsal aorta prior to their
release into circulation and eventual long-term colonization
of fetal liver and marrow, thus corroborating the intra-
embryonic origin of HSC [43, 53, 55, 57, 96–101]. IAHC
have been shown to appear around E9.5 in the AGM, and
peak emergence of HSC from them occurs between E10.5
and E11.5 [21–23, 96].
The cellular composition and function of IAHC before
and during HSC detection has been investigated, although
to date a unified cell surface marker profile of HSC gen-
erated within the embryo has not been identified,
presenting an important roadblock to furthering our
understanding of EHT. IAHC at E10.0 were found to be
phenotypically heterogeneous and contain very few pro-
genitors (average of 22), but notably contain pre-HSC
(average of 12) capable of long-term multilineage
hematopoietic reconstitution post-transplantation [102]. A
collection of hematopoietic, stem, and endothelial markers
such as c-Kit, CD31, CD34, SCA-1, MAC1, VE-cadherin,
Tie2, Flk-1 and CD45 have been shown to be expressed by
HSC within the embryo, but these are also found on other
cell types [47, 57, 99, 103–106]. Intra-aortic hematopoietic
clusters have also been shown to be composed of pre-HSC
that differentially express endothelial and hematopoietic
surface markers including VE-cadherin, c-Kit, Ly6a, CD41
and CD45, suggesting that a post-hemogenic endothelial
cell intermediate may exist along the transition from
endothelial cell to HSPC within these intra-aortic clusters
[53, 102, 106–108]. The remaining cell types within IAHC
are yet to be identified, but are hypothesized to be com-
prised of these immature pre-HSC that will mature toward
a HSC fate via EHT. Once the hematopoietic cluster phase
of EHT is complete, data from chick studies show that the
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splanchnopleural endothelium in the aortic floor is replaced
by somitic endothelial cells, in part offering an explanation
for the very brief timeframe in which vascular hemato-
poiesis occurs during development [109], although this has
not been shown in mouse models [110].
The dorsoventral polarity of IAHC emergence appears
to be critical to governing their ultimate hematopoietic fate.
This has been shown in the chick [111] and mouse [112] to
be guided by local presence of mesenchymally derived pro-
hematopoietic ventralizing (VEGF, bFGF, TGF-b, BMP4)
or anti-hematopoietic dorsalizing factors (EGF and TGF-
a), the downstream effects of each impact the expression of
critical hematopoietic transcription factors that are
involved in EHT [14, 111, 112]. Importantly, sub-aortic
mesenchyme has not been shown to be a direct source of
hematopoietic cells [45], thus corroborating the importance
of these locally derived factors in driving hematopoietic
specification of vascular endothelial cells. HSC have been
found to have particular enrichment in the middle third of
the E11.0 dorsal aorta, immediately adjacent to origin of
the vitelline artery, suggesting that a disturbance in flow at
the junction of these two vessels may interact with
microenvironmental signals to drive HSC emergence
[113]. The presence of hematopoietic mediators such as
RUNX1 in the ventral aortic mesenchyme [56, 57], and
upregulation of genes involved in cell death, adhesion,
migration, as well as vascular development and hemato-
poiesis [113], coupled with restriction of definitive HSC
localization to the ventral aorta [99] and evidence
demonstrating that para/peri-aortic supporting cells also
promote hematopoiesis [111, 112, 114–116], suggests that
within the AGM there likely exists a specialized
hematopoietic microenvironment or niche [117] powered
by master transcriptional regulators, their downstream
effectors, and extrinsic modifiers of these signaling cas-
cades such as fluid shear stress [118, 119] that promote
initial HSC development from hemogenic endothelium—
these are reviewed below.
RUNX1
RUNX1 (AML1) is a sequence-specific DNA binding
protein that is part of a family of transcription factors
called core binding factors (CBF), and an essential master
regulator of EHT during aortic hematopoiesis [58, 120–
122]. Consistent with a role in EHT, RUNX1 deficiency in
embryonic stem cells prevents the formation of blood cells
from hemogenic endothelium [42]. It is expressed in all
sites of definitive hematopoiesis in the embryo and pre-
cedes emergence of HSPC. Interestingly, this is conserved
across all vertebrate species studied [123]. RUNX1 is
expressed by mesenchymal cells in the dorsal aorta and
AGM, placenta, and in hematopoietic cell clusters in
ventral-dorsal aorta and vitelline and umbilical arteries [56,
57, 123], but its requirement, while critical for normal
definitive hematopoietic development [124–126], as pre-
viously reviewed [14], is transient in embryonic
development, and is not required during primitive hema-
topoiesis [42, 121] or after EHT [58]. RUNX1 expression
has been shown to repress the endothelial program, while
activating the hematopoietic program, as evidenced by
sequential emergence of hematopoietic markers CD41 and
later CD45 [42, 106, 108], at the time of transition from
hemogenic endothelial cells to a hematopoietic cell fate
[120, 123]. Deletion of Runx1 does not prevent emergence
of the CD41 marker on VE-cad?CD45-cells, but has been
shown to prevent transition of these cells to
CD41?CD45? [127]. This patterned transition from
endothelial cell phenotype to a hematopoietic phenotype is
in part controlled by binding of multiprotein complexes
containing GATA, Ets (PU.1) [128], and SCL family fac-
tors to Runx1 enhancers known to be involved in HSC
emergence [14, 129, 130] and is also marked by loss of
expression of genes associated with arterial identity, such
as Sox17 and Notch1 [131], further supporting the idea of
temporal transcriptional regulation governing cell fate as a
central tenet of EHT.
Prospective isolation and transcriptional analysis of
murine hemogenic endothelial cells using a transgenic
Runx1 enhancer-GFP reporter model has demonstrated that
beginning at E9.5, hemogenic endothelial cells commit to
hematopoietic lineage in an ordered fashion marked by an
early gradual loss of endothelial potential and increase in
hematopoietic potential. This occurs while the hemogenic
endothelial cells still remain part of the endothelial wall
[59]. The different stages of the transition from endothelial
to hematopoietic cell have also been shown to be guided by
the transcriptional activity of Runx1’s two [132] promoter
regions: the P1 (distal) and P2 (proximal) Runx1 promoters
control expression of Runx1c (distal) and Runx1b (proxi-
mal) isoforms [133, 134]. RUNX1b is expressed at low
levels in hemogenic endothelium until E10.5 [135, 136],
whereas RUNX1c expression is initiated within HSPC and
loss of endothelial phenotype [133, 134, 136]. The P1
promoter element associated with RUNX1c expression is
more complex than the P2 promoter and contains many
binding sites for hematopoietic transcription factors [132].
RUNX1b transcriptome analysis reveals that it activates
genes associated with cell adhesion, ECM remodeling,
integrin signaling, and endothelial cell migration at the
onset of transition from hemogenic endothelial cells to
HSPC [133]. RUNX1 downstream targets such as GFI1/
GFI1B are also thought to promote down-regulation of
endothelial proteins, thereby promoting a morphologic
change from flattened endothelial cells to round cells [137].
Lack of GFI1B in embryos results in failure of release of
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hematopoietic cells from the extraembryonic yolk sac
vasculature into circulation [137]. Generation of P1 and P2
RUNX1-EGFP zebrafish reporter lines demonstrated ery-
thromyeloid progenitor emergence from the posterior
blood island at 18hpf in the P1 line and definitive HSC
emergence in the AGM region at 22hpf in the P2 line,
further underlining the role of alternative Runx1 promoter
usage in cell fate determination via generation of spatially
segregated yet temporally successive HSPC emergence
[138]. Other work further demonstrated that the RUNX1c
isoform was indeed only expressed at the time of emer-
gence of definitive HSC (E10.5-11.5) in the mouse AGM
and human (embryoid body day 12), but retroviral over-
expression of both RUNX1 isoforms in mouse marrow and
liver HSPC demonstrated no functional difference between
either isoform in further generation of HSC, and induced
quiescence in mouse HSC in vitro and in vivo. This sug-
gests a developmentally important timeframe for the
RUNX1c isoform in specification of HSPC from hemo-
genic endothelial cells at the time of EHT [139]. Other
studies have identified a role for blood flow induced shear
stress as a regulator of Runx1 expression by the endothe-
lium [118, 119].
Studies utilizing conditional deletion of Runx1, driven
by Vav1 promoter expression, a pan-hematopoietic gene,
demonstrate that its hematopoietic requirement only
extends through the transition from endothelium to HSPC
[58]. Dependence on RUNX1 for generation of ery-
thromyeloid progenitor cells begins at E7.5 [140] and ends
around E10.5 [141]. Further study of requirement for
RUNX1 in hematopoietic development utilized timed
endothelial-specific deletion of RUNX1 activity showed
that the transition to RUNX1 independent HSC formation
occurs around E11.5 and does not require fetal liver col-
onization [141]. Tissue-specific restoration of RUNX1
function in murine Tie-2-expressing cells allowed for res-
cue of embryonic definitive HSC potential, allowing
mutants to survive until birth without the previously
described hemorrhagic phenotype observed in Runx1 null
embryos. These observations suggest that the primary
embryonic lethal defect in Runx1 mutants is indeed
hematovascular in nature [142]. In adults, deletion of
Runx1 does not cause a reduction in HSPC numbers in the
marrow; in fact, it causes an expansion of these cell types
[123] and leads to hematologic abnormalities, such as
increased myeloproliferation with neutrophilia, thrombo-
cytopenia, and increased extramedullary hematopoiesis
[143]. In the absence of RUNX1 during development,
primitive erythropoiesis proceeds normally, hemogenic
endothelium develops, but neither generation of myeloid
and lymphoid progenitors, nor HSC generation occurs
(reviewed in [14]), leading to an absence of IAHC and fetal
liver HSC [54, 56, 57, 144], and ultimately death by E12.5
[144]. Interestingly, studies of hematopoietic tissues from
Runx1 haploinsufficient embryos yields variable degrees of
HSC generation depending on the tissue type isolated, such
that cultured mutant AGM explants yield fewer HSC than
wild-type, and yolk sac and placental tissues yield
increased numbers of HSC [145]. On the other hand,
AGM-derived HSC from Runx1 haploinsufficient mice that
are directly transplanted into irradiated recipients without
an intermediate culture step demonstrates increased gen-
eration of HSC [57]. Collectively, this body of evidence
strongly supports a role for RUNX1 as a critical regulator
of EHT, and that modification of its expression via inter-
action with associating proteins within specific tissue
microenvironments and developmental time points, as well
as under different physiologic conditions, impacts regula-
tion of the hematopoietic transition [14, 124, 145].
SCL/LMO/GATA
The regulatory regions of hematopoietic genes are known
to be bound by RUNX1, as discussed, as well as a tran-
scription factor complex composed of stem cell leukemia
protein (SCL)/T cell acute lymphocytic leukemia protein-1
(TAL-1), LIM domain only 2 (LMO2), GATA1, and
GATA2 ([1, 140, 146–148], all of which have been
implicated in EHT. LMO2 is thought to act as a bridge
between SCL/TAL-1 and GATA-binding proteins in a
transcriptional activating complex that drives vertebrate
hematopoietic specification (reviewed in [1]).
Studies of Scl/Tal-1, Lmo2, and Gata1/2 mutant mouse
embryos demonstrate that deletion of each gene results in
midgestation lethality and impaired definitive hematopoi-
esis [149–152]. SCL is a helix-loop-helix transcription
factor that functions upstream of RUNX1, and has been
shown to be a critical regulator of hematopoiesis via gen-
eration of Tie-2hi c-Kit?CD41- hemogenic endothelium
[42].
SCL loss-of-function studies show that hematopoiesis is
impaired at both the level of stem cell formation and
subsequent differentiation [153]. Interestingly, multiple
isoforms of SCL [SCLA (full length) and SCLB (N-ter-
minal truncated)] have been identified [153], and may play
differential roles in definitive hematopoiesis. In vivo time
lapse imaging studies demonstrated selective SCLB iso-
form expression in the dorsal aorta of hemogenic
endothelium just prior to EHT, and this isoform may act
upstream of RUNX1 to mediate EHT. SCLA, on the other
hand, is expressed in HSC after the EHT process, and is
critical for maintenance of these newly born cells within
the AGM [153].
GATA2 is expressed by the para-aortic splanchnopleura
and AGM regions of the mouse embryo [154]. It has been
shown to have a role in production and expansion of HSC
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in the AGM during embryogenesis as well as normal
expansion of the adult HSC pool within the bone marrow
[155]. Gata2 deficient mice die at E10.5 due to defective
primitive erythropoiesis and lack of HSPC generation
[151]. Conditional deletion of a Gata2 cis regulatory ele-
ment in mouse AGM results in reduced expression of
hematopoietic transcription factors SCL and RUNX1, and
hemogenic endothelial cells of the mutants fail to generate
HSPC, leading to embryonic lethality by E13-14 [156].
Additionally, VE-cadherin-driven deletion of Gata2 pre-
vents generation of intra-aortic clusters in mouse dorsal
aorta and results in a deficiency of long-term repopulating
HSC [157]. Embryonic stem cells derived from adult chi-
meric mice deficient in LMO2 also fail to contribute to the
endothelium of large vessels [158, 159] and blood cell
production [158, 159]. Morpholino knockdown of either
Scl [147] or Lmo2 [160] in zebrafish results in similarly
impaired expression of hematopoietic genes and loss of
IAHC. Collectively, these findings implicate this group of
transcription factors as having essential roles in EHT and
definitive hematopoiesis.
Notch
In addition to the previously discussed role for Notch
signaling in hemogenic specification, Notch has also been
shown in a number of vertebrate studies to be essential for
definitive HSC emergence in the embryo [87, 161, 162]. It
is thought that Notch signaling mediates HSC development
via EHT by interactions between emerging HSPC
expressing Notch receptors and underlying endothelial
cells and stroma expressing Notch ligands [163, 164].
Notch1 and Notch4 receptors are expressed specifically in
the endothelial cell layer of the dorsal aorta, and Notch
signaling pathway components such as DLL4, Jag1, Jag2,
HES1, HRT1, HRT2, and GATA2 are expressed in both
the endothelial cell layer of the dorsal aorta and its
emerging hematopoietic clusters beginning between E9.5
and E10.5 [165–167]. Mouse and zebrafish embryos that
lack Notch signaling components demonstrate defective or
absent definitive intra-embryonic hematopoiesis and
inability to establish permanent self-renewing HSC (re-
viewed in [1, 165]). In-vitro blockage of Notch signaling
using DAPT has been shown to prevent EHT of cultured
murine E9.5 pSP/AGM cells [163]. Activation of Notch
signaling in a modified culture system of E11.0 pSp/AGM
hemogenic endothelial cells on immobilized chimeric
human DLL1 results in emergence of multilineage
hematopoietic progenitor formation with long-term
engraftment capability [163], further supporting the critical
role of Notch in driving early hematopoiesis.
HSC generation in the hematopoietic clusters of the
murine AGM has been shown to mostly depend on Notch
ligand Jag1 and its regulation of Gata2 expression [167].
The Gata2 promoter region contains two RBPJ binding
sites involved in Notch-mediated activation [168] and not
surprisingly, deletion of Notch transcriptional co-activator
RBPJ leads to loss of HSPC, as well as loss of GATA2
expression, which is necessary for continued differentiation
of hematopoietic cells [166, 169]. Notch-dependent
GATA2b expression has been demonstrated to be required
for RUNX1 expression within zebrafish dorsal aorta from a
very early developmental stage, and its expression is lim-
ited to emerging HSC [170]. Embryos deficient for Notch1
downstream targets HES1 and HES5 have been shown to
have intact arterial specification but have notable he-
matopoietic defects marked by abnormal proliferation of
nonfunctional HSPC and increased expression of
hematopoietic regulators including GATA2, RUNX1, and
c-Myb [168]. Further interrogation of the Gata2 promoter
region in this study revealed that in addition to containing
RBPJ binding sites essential for initiation of hematopoiesis,
it also contained HES binding sites necessary for Gata2
downregulation involved in driving functional hematopoi-
esis [168]. This highlights the complexity of Notch
signaling in this context, as both driving expression of and
concomitantly negatively regulating a key hematopoietic
mediator.
Previous work showing that different Notch ligands
confer different signal strengths [171, 172] has formed the
basis for recent work suggesting that determination of
endothelial versus hematopoietic fate in the developing
AGM is mediated by ligand-specific differences in Notch1
signal strength. Use of high and low sensitivity Notch1
activation trap mouse models demonstrated that
hematopoietic specification and repression of the endothe-
lial program is driven by low levels of Jag1 mediated Notch
signaling. In the absence of Jag1, DLL4 mediated high
levels of Notch activity instead drives the endothelial/ar-
terial program [173]. The authors of this study propose a
model wherein Jag1 antagonizes DLL4-mediated high
Notch signaling in a subset of endothelial cells to drive them
toward a hematopoietic fate rather than an endothelial fate
[173]. This further highlights the critical role of Jag1, as
previously discussed, in driving EHT and importantly also
adds to the body of evidence that endothelial and
hematopoietic cells represent distinct lineages.
In human embryonic stem cells, Notch activation has
also been demonstrated to be necessary for generation of
CD45 ? cells, and Notch signaling via HES1 is necessary
for their hematopoietic differentiation [174]. Other studies
in human embryonic stem cells showed that ligand DLL4 is
induced via Notch signaling in a small subset of endothelial
progenitors during hematopoietic differentiation, and the
level of DLL4 expression appears to correlate with
hematopoietic versus endothelial fate. That is, DLL4-high
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progenitors are enriched for endothelial potential, whereas
DLL4low/- coincides with acquisition of hematopoietic
potential [174]. Thus, a model has been proposed, wherein
hemogenic endothelial cells are DLL4low/- and are Notch
activated via neighboring DLL-high cells to promote
transition from an endothelial state to CD45? hematopoi-
etic cells that cluster in a fashion similar to intra-aortic
hematopoietic clusters in the AGM [174]. Related studies
also demonstrated a functional role for DLL4 in promoting
specification of hematopoietic cells from hematoendothe-
lial progenitors, wherein expression of DLL4 increased
numbers of clonogenic hematopoietic progenitors, and
interestingly skewed their fate toward an erythroid lineage
[174]. No correlation between levels of Jag1 or Jag2
expression was noted with respect to generation of hema-
toendothelial progenitors or hematopoietic precursors there
from, as has been noted in other vertebrate studies, sug-
gesting that human HSC differentiation may be affected by
other Notch ligands [174].
A recent study investigated Notch-regulated elements
involved in control of HSC generation in zebrafish, mouse,
and human embryonic tissues. ChIP on ChIP analysis
against Notch co-activator RBPJ was performed and
identified candidate promoter regions of genes regulated by
Notch in hemaotpoietic tissues. The most significant result
was enrichment of Cdca7, which is shown to recruit RBPJ,
as well as Notch1 ICD. CDCA7 expression was shown to
be upregulated in the hemogenic population derived from
human embryonic stem cells in a Notch-dependent manner.
Down-regulation of Cdca7 mRNA was shown to induce
hematopoietic differentiation and concomitantly decrease
HSPC numbers, suggesting that it is a Notch-mediated
target involved in emergence of HSPC, but not differenti-
ation of these cells [175].
Wnt/b-catenin
There is evidence that Notch, Wnt, and BMP pathways
interact to generate HSC in the zebrafish embryo and also
are involved in driving hematopoietic development from
embryonic stem cells [176, 177]. Wnt is a well-described
evolutionarily conserved signaling pathway known to
modulate many areas of embryonic development. The Wnt
ligands are a family of 19 glycosylated proteins that bind
Frizzled receptors and LDL receptor protein co-receptors
to trigger a variety of downstream responses including
activation of b-catenin (canonical pathway) and/or JNK
and PKC (noncanonical pathway) that modulate gene
expression programs critical for normal embryonic devel-
opment (reviewed in [176]). Early evidence that Wnt/b-
catenin has a role in embryonic hematopoiesis came from
zebrafish studies showing Prostaglandin E2 mediates HSC
formation in the AGM via b-catenin [177]. Recently, it has
been shown that EMP cells emerging from vascular
endothelium in the yolk sac do so independent of vascular
identity or the influence of circulation, but their emergence
requires intact Wnt signaling [12]. It has been shown that
Wnt/b-catenin activity is transiently required in the AGM
of mouse embryos for emergence and generation of long-
term HSC, as well as production of hematopoietic cells
in vitro from AGM endothelial precursors [176]. Hemo-
genic endothelial cells from AGM at E11.5 have also been
shown to have a high degree of active Wnt signaling, as
evidenced by the presence of high levels of b-catenin in
cells lining the dorsal aorta, close to emerging
hematopoietic clusters, but not in cells budding off of
endothelium or within circulating plasma [75]. In human
pluripotent stem cell models of EHT, hemogenic
endothelium undergoes EHT toward either a primitive or
definitive hematopoietic fate depending on presence of
either inactive (primitive) or active (definitive) Wnt sig-
naling [178]. This body of evidence suggests a context-
specific role for Wnt such that it is required for the gen-
eration of hemogenic endothelium and likely initiation of
EHT but gradually becomes downregulated as HSPC are
generated [75].
HOX/SOX
Homeobox genes, such as Hox and Sox genes, play a key
role in determining cell identity during embryonic devel-
opment [179–182]. Hox paralogue group 3 (HOXA3),
specifically, has an important role in endothelial and car-
diovascular development (reviewed in [183]). Its expression
was found to be high in embryonic mesenchymal tissue,
intermediate in the dorsal aorta and absent from the yolk sac
at E8.25 and E8.5 when definitive hematopoiesis is occur-
ring in that tissue. This is consistent with the idea that it
prevents hematopoietic differentiation of endothelial pro-
genitors via down-regulation of RUNX1, GATA1, GFI1b,
Ikaros and PU.1. Conversely, downregulation of HOXA3 is
concomitant with increased RUNX1 expression within the
aortic endothelium, and its re-expression in embryonic stem
cells, as well as cultured mouse embryonic tissues, causes
retention of an endothelial phenotype. These data suggest
an important role for HOXA3 in maintenance of an
endothelial state prior to hematopoietic transition [183].
Ectopic expression of another Hox paralogue, HOXB4, in
yolk sac derived hematopoietic progenitor cells has been
shown to drive conversion to a definitive HSC phenotype
with long-term engraftment potential [184]. Additionally,
several transcriptional regulators of the definitive
hematopoietic program such as RUNX1, SCL/TAL1,
GATA2, and GFI1 have been shown to be direct targets of
HOXB4 in embryonic stem cell-derived hematopoietic
progenitors [185].
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SOX17 is a transcription factor expressed in AGM
hemogenic endothelium downstream of HOXA3 [183] at
E8.5–8.75, and in addition to its role as a critical factor
governing arterial identity [186], it has been shown to be
required for generation of fetal and neonatal HSC [187].
Although SOX17 is not required for the generation of adult
HSC [120], its overexpression in adult hematopoietic pro-
genitors has been shown to confer fetal HSC characteristics
[188]. Additionally, SOX17 can drive expansion of cells
that exhibit downregulation of endothelial markers and also
possess an ability to generate hematopoietic cells [120,
187, 189]. Loss of Sox17 decreases expression of Notch1 in
the murine AGM, suggesting that SOX17 mediates gen-
eration of hemogenic endothelium via Notch signaling
during definitive hematopoiesis [187]. Conditional loss of
SOX17 mediated repression of Runx1 and Gata2 recently
has been shown to result in increased production of
hematopoietic cells from murine AGM endothelial cells
that can be dampened by an increase in Notch signaling
[131], suggesting that following hemogenic specification,
SOX17 modulates hemogenic endothelium by active
repression of the hematopoietic program by the SOX17/
Notch axis until initiation of EHT. This has been com-
plemented by studies of murine AGM hemogenic
endothelial cells undergoing EHT using combined
correlative scanning electron microscopy and immunoflu-
orescence demonstrating an increase in RUNX1 levels
concomitant with decrease in nuclear SOX17, rounding of
previously flattened AGM endothelial cells, and the onset
of co-expression of CD41 and c-Kit on these newly roun-
ded cells [190]. SOX17 has also recently been shown to be
necessary for commitment to the definitive erythroid lin-
eage [191]. Other closely related SOX family members,
SOX7 and SOX18, have a role in primitive hematopoiesis.
SOX7 and SOX18 have transient expression in
hematopoietic precursors at the onset of blood specification
and expression of these in early hematopoietic precursors
from mouse embryonic stem cells and embryos enhances
their proliferation while blocking their maturation [189,
192, 193].
cMyb
The transcription factor cMyb was originally identified as a
nuclear protooncogene involved in certain avian cancers but
is also expressed in HSPC prior to their differentiation.
Multiple mouse studies utilizing cMybmutants demonstrate
the key role played by cMyb within a variety of
hematopoietic pathways such as lymphoid development,
HSPC maintenance, and HSPC differentiation [194].
Deletion of cMyb results in murine embryonic lethality at
E15.5 due to lack of fetal liver hematopoiesis, specifically
impaired erythroid and myeloid development [195]. AGM
explants from cMyb–/– mutant mice also yield 100-fold
fewer HSPC [196]. Loss of function studies in zebrafish
have shown similarly impaired definitive hematopoiesis,
even in the setting of otherwise normal primitive hemato-
poiesis [197, 198]. Zebrafish studies have also demonstrated
accumulation of HSPC within the ventral wall of the dorsal
aorta, their site of origination, and that this failure of
migration to a hematopoietic niche such as the zebrafish
caudal hematopoietic tissue and kidney may in part underlie
the previously demonstrated failure of definitive hemato-
poiesis in cMyb mutants [194].
Other mediators of HSPC generation
from hemogenic endothelium
G-protein coupled receptors
To identify candidate regulators of EHT on a global level,
whole genome transcriptome analysis of murine aortic
endothelial cells, hemogenic endothelial cells and HSPC
populations has identified 530 differentially expressed
genes during EHT with particular upregulation of the gene
encoding G protein coupled receptor 56 (Gpr56) and
heptad transcription factors SCL, LYL1, LMO2, GATA2,
RUNX1, ERG, and FLI-1) [199, 200]. The heptad factors
were been shown to bind to Gpr56 enhancer regions and
regulate its expression, and knockdown of Gpr56 in zeb-
rafish resulted in hematopoietic defects that could be
rescued with either mouse or zebrafish Gpr56 RNA, thus
establishing GPR56 as a novel regulator of EHT via a yet
to be elucidated mechanism [199]. Another G protein
coupled receptor, GPR183, has also recently been shown to
dampen Notch signaling in zebrafish models via its
recruitment of b-Arrestin-1 and E3 ligase NEDD4, both of
which degrade Notch1 in hemogenic endothelial cells to
promote EHT [201].
Purine signaling
Purines (such as adenosine, ADP, and ATP) exhibit
extracellular signaling activity that regulates diverse
physiologic and developmental cellular functions including
autoregulation of blood flow, cell proliferation and differ-
entiation, and stem cell regeneration, all via cell surface
receptors [202]. Adenosine signaling at the level of the
vascular endothelium has recently been demonstrated to
play a role in regulation of HSPC development in both
zebrafish and mice. In a recent study, elevated adenosine
levels in zebrafish embryos were shown increase numbers
of RUNX1?/cMyb? HSPC in the dorsal aorta via
increased expression of CXCL8 (IL-8), which has been
shown to trigger proliferation of hematopoietic progenitor
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cells [203]. Furthermore, in the same study, alteration of
adenosine signaling via knockdown of the A2b adenosine
receptor resulted in disruption of both the generation of
SCL? hemogenic vascular endothelium and the endothe-
lial to hematopoietic transition. These results were
mirrored in mouse embryonic stem cell colony forming
assays, as well as E10.5 AGM explants, that demonstrated
an increase in production of multipotent progenitor colo-
nies in the setting of increased adenosine signaling [202].
Chromatin remodeling
The role of reprogramming of transcriptional states in
promoting lineage commitment in HSC continues to be of
great interest in the field. The role of chromatin modifi-
cation as an important mediator of transcriptional
regulation of EHT has been investigated. Majumder and
coworkers demonstrated that the histone chaperone HIRA
(histone cell cycle regulation-defective homolog A) regu-
lates RUNX1 activity during EHT. They showed that
HIRA mediated histone acetylation of Runx1 activates the
downstream hematopoietic targets of RUNX1 and that in
HIRA deficient mutants, there was not only reduced
expression of Runx1, but also lack of chromatin reorgani-
zation necessary for appropriate RUNX1 binding and
transcriptional activity to drive hematopoiesis [204].
Chromodomain helicase DNA-binding protein 1 (CHD1),
an ATP-dependent chromatin-remodeling enzyme whose
activation is associated with an increased level of total
active transcription in mouse embryonic stem cells [205,
206] has also recently been shown to be essential for
successful EHT. Endothelial-specific Chd1 mutants, while
able to produce intact E10.5 IAHC, that show intermediate
markers of differentiation such as RUNX1 and c-Kit, do
not successfully initiate definitive hematopoiesis and die by
E15.5 due to severe anemia and absolute failure of ery-
thropoiesis [207]. Analysis of cells from the mutant IAHC
demonstrated that the cells in the clusters underwent
apoptosis rather than hematopoietic specification, as evi-
denced by failure of expression of markers of
hematopoietic lineage such as CD45, and a fivefold
reduction in myeloid colony forming potential. Global gene
expression analysis of Chd1 mutant endothelium at E10.5
in this study was generally found to be unchanged when
compared to wild-type endothelial controls, but notably
lacked activation of a set of 156 genes implicated in
hematopoiesis and growth. Furthermore, hematopoietic
progenitors underwent a CHD-1 dependent elevation in
global transcriptional at the time of EHT that was neces-
sary for initial expansion and survival of HSPC but not for
differentiation and maintenance of the differentiated HSC
pool [207]. Committed hematopoietic progenitors with a
Vav-Cre Chd-1 mutation demonstrated peripheral blood
composition comparable to wild type mice at one year of
age. Taken together, these results suggest a pointed critical
role for CHD-1 mediated increased transcriptional output
in order to successfully complete EHT and establish
functional hematopoiesis, but that it is not required beyond
the point of hematopoietic specification [207].
Hypoxia and inflammation
The intrauterine environment is notably hypoxic and via
the action of hypoxia inducible factor transcription factors
(HIF), transcription of genes necessary for promoting
normal development in this environment is activated (re-
viewed in [208]). The midgestation AGM and placenta
have been shown to exhibit localized areas of hypoxia
including hematopoietic clusters and some underlying
endothelial cells. The role of HIF1a in regulation of
embryonic hematopoiesis was recently shown to be nec-
essary for generation of HSPC from the AGM from E9.0 to
E11 [208].
Recently, an interesting link between Toll-like receptor
4 (TLR4) inflammatory signaling, a cascade previously
associated with stress-induced hematopoiesis in adult
marrow, and embryonic hematopoiesis has also been
established. TLR4-NF-jB signaling was found to regulate
hemogenic endothelium-derived HSPC development in
both mice and zebrafish embryos via activation of Notch
signaling [209]. This complements other recent studies
investigating the role of non-infectious/sterile pro-inflam-
matory signaling via TNFa or interferon in HSPC
development in zebrafish and mice [210–212], suggesting
that a low-grade pro-inflammatory state is necessary for
normal HSPC emergence even under low-stress conditions
and may in fact prime the hematopoietic system for reactive
hematopoiesis in the setting of exogenous stressors such as
infection [209].
Summary and conclusions
In summary, the developmental hierarchy governing
hematovascular development is complex and multifactorial
and our understanding of it is still in its infancy. Over time
the study of hematologic development has founded many
concepts central to the field of stem cell research as a
whole [213]. Hematopoietic development begins early in
the mammalian embryo in the extra-embryonic yolk sac
and placenta and peaks in the AGM region by E10.5. It is
characterized by overlapping waves of generation of
primitive blood cells, multilineage hematopoietic progeni-
tor cells, and finally definitive long-term repopulating HSC
via a hemogenic endothelial cell intermediate. Emergence
of blood cells from hemogenic endothelium is known as
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the endothelial to hematopoietic transition, which is driven
by an incredibly complex and yet to be fully elucidated
interplay between developmental timing and tissue
microenvironmental factors. This interplay is thought to
govern a timed gradual loss of endothelial characteristics
[105], accompanied by changes in level and type of
expression of hematopoietic regulators such as RUNX1
[56, 99, 142] beginning in the extraembryonic yolk sac,
placenta and umbilical vessels, as well as the midgestation
aorta, and possibly being completed in hematopoietic
niches such as the fetal liver, and bone marrow [18, 19, 99,
102, 105, 106].
Still, there remain a number of unanswered questions
surrounding the progression from embryonic mesoderm to
endothelium to HSPC and adult HSC. Of particular inter-
est, as already mentioned, is study of the tissue specific
microenvironments in which these progenitor cells are
generated and mature during development, and the role that
microenvironment plays in driving the formation of mul-
tilineage HSPC [29]. To date, there is little evidence to
support the existence of hemogenic endothelium in later
stages of embryonic development or postnatally, but
human cord blood hematopoietic progenitors have been
shown to differentiate into endothelial precursors capable
of generating functional vasculature in vivo and if further
instructed by hematopoietic growth factors, first switch to
transitional CD144? CD45? cells and then to
hematopoietic cells perhaps due to the influence of their
tissue microenvironment [214]. This finding is of great
interest, as it suggests that hemogenic endothelium is not as
transient in nature as previously thought and may exist
beyond the embryonic period as an untapped reservoir of
hematopoietic potential for therapeutic applications [214].
Efficient generation and differentiation of hematopoietic
cells in vitro to date has been fraught with technical diffi-
culty and this difficulty is almost certainly exacerbated by a
need for a more complete understanding of in vivo
endothelial and hematopoietic development (reviewed in
[215]).
Further study of these processes, from specification of
hemogenic endothelium to generation of HSPC via EHT,
and establishment of functional definitive hematopoiesis
both in the prenatal and postnatal period, will further our
understanding of developmental hematopoiesis, as well as
adult hematopoiesis in both health and disease. It will also
highlight the cellular and molecular underpinnings of the
evolution of a population of stem and progenitor cells that
hold great promise for use in clinical therapies for hema-
tologic, oncologic, vascular, and immune-mediated
pathologies.
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